ORALONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORALONE (ORALONE).
ORALONE is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory cytokines.
| Metabolism | ORALONE is primarily metabolized in the liver via CYP3A4 to inactive metabolites, which are excreted in urine and bile. |
| Excretion | Renal: >90% as glucuronide conjugates and unchanged drug (approximately 60% as metabolites, 30% unchanged). Biliary/fecal: <5%. |
| Half-life | 1.5–3 hours (mean 2.5 hours) in adults; prolonged to 3–6 hours in hepatic impairment and up to 4 hours in elderly patients. |
| Protein binding | 70–80% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 0.4–0.6 L/kg (approximately 30–40 L in a 70 kg adult), indicating moderate tissue distribution. |
| Bioavailability | Oral: 60–75% (first-pass metabolism reduces systemic availability). Topical mucosal: variable but higher local absorption; systemic absorption <1%. |
| Onset of Action | Oral: 30–60 minutes to initial clinical effect; peak effect at 1–2 hours. Topical (mucosal): within 5–15 minutes. |
| Duration of Action | 4–6 hours for oral formulation; topical mucosal effect lasts 2–3 hours after a single application. |
0.3-0.6 mg/kg IV/IM every 4-6 hours as needed; maximum single dose 30 mg.
| Dosage form | PASTE |
| Renal impairment | CrCl 30-60 mL/min: reduce dose by 25%; CrCl <30 mL/min: reduce dose by 50% and extend interval to every 8 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | Children <6 months: 0.1-0.2 mg/kg IV/IM every 4-6 hours; 6 months-12 years: 0.2-0.5 mg/kg IV/IM every 4-6 hours; maximum single dose 15 mg. |
| Geriatric use | Reduce initial dose by 50% (maximum 15 mg per dose) and titrate cautiously due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORALONE (ORALONE).
| Breastfeeding | Prednisolone excreted into breast milk in low amounts; M/P ratio ~0.2-0.5. Estimated infant dose <10% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for adrenal suppression (e.g., poor weight gain, lethargy). |
| Teratogenic Risk | ORALONE (prednisolone) is a corticosteroid. First trimester: Increased risk of cleft palate (OR 3.4, 95% CI 1.5-7.7) with systemic use; risk is dose-dependent. Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Avoid high doses during pregnancy if possible. |
■ FDA Black Box Warning
No black box warning has been issued for ORALONE.
| Serious Effects |
["Hypersensitivity to any component of the formulation","Untreated infections (bacterial, viral, fungal)","Use in the eyes"]
| Precautions | ["Systemic absorption may occur with prolonged use on large areas or under occlusive dressings.","Local adverse reactions include burning, itching, irritation, dryness, and atrophy.","Avoid use in the presence of untreated bacterial, viral, or fungal infections.","Use with caution in patients with a history of hypersensitivity to corticosteroids."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose, blood pressure, signs of infection, and adrenal function. Fetal monitoring for growth restriction via ultrasound; assess for preterm labor symptoms. In neonates: observe for hypoglycemia, hypoadrenalism. |
| Fertility Effects | High-dose corticosteroids may disrupt menstrual cycle and ovulation via suppression of hypothalamic-pituitary-ovarian axis, but reversible upon dose reduction. No evidence of permanent infertility. |